|
 |
|
 |
|
|
2006 Press Releases |
|
|
|
|
|
|
|
4/5/06: Oxford
Ventures Announces Completion of Merger with ULURU |
|
|
|
|
|
|
|
- Name
Change to ULURU Inc.
- Symbol
Change on the OTC Bulletin Board: ULUR
-
Implementation of Reverse Stock Split
|
|
|
|
DALLAS, April 5 /PRNewswire-FirstCall/
-- Oxford Ventures, Inc. (OTC Bulletin Board: OXFV - News;
"OXFORD") today announced that its merger with ULURU, Inc.
("ULURU") has been completed. Under the terms of the merger
agreement, ULURU has been merged into a subsidiary of
Oxford, with Oxford being the surviving legal entity. Oxford
has acquired all of the outstanding shares of ULURU in
exchange for unregistered common stock of Oxford. |
|
|
|
|
|
|
|
Oxford's name
has been changed to ULURU Inc. and the new company
headquarters are located at 4452 Beltway Drive, Addison,
Texas, 75001. |
|
|
|
|
|
|
|
Mr. Kerry P.
Gray will be President and C.E.O. of ULURU. Additionally,
Mr. Gray will serve on the Board of Directors along with:
|
|
|
|
|
|
|
|
|
|
|
|
Effective April
5, 2006 the trading symbol on the OTC Bulletin Board will
change from OXFV to ULUR. Additionally, the company has
implemented a 1-for-400 reverse stock split. The reverse
stock split will take effect and the shares will begin
trading on a post-split basis at the opening of business on
Wednesday, April 5, 2006. |
|
|
|
|
|
|
|
With the
completion of the merger and the reverse stock split the
company will have approximately 13 million common shares
outstanding. Shareholders will be notified by Continental
Stock Transfer & Trust Company, ULURU's stock transfer
agent, regarding the process for receiving new share
certificates. |
|
|
|
|
|
|
|
ULURU's business
plan is to establish a market leadership position in the
development of wound management, plastic surgery and oral
care products utilizing innovative drug delivery solutions
to improve clinical outcomes for patients and provide an
economic benefit to healthcare providers. The company
intends to establish a sales and marketing organization to
market our product developments to the wound management and
plastic surgery markets and to form strategic partnerships
to market our range of oral products and other product
developments that require a large sales organization.
Acquiring and licensing products for wound management and
plastic surgery is an integral component of our strategy of
rapidly building a sales and marketing organization. |
|
|
|
|
|
|
|
Commenting on
the recent developments, Kerry P. Gray, President and C.E.O.
of ULURU, stated, "With the completion of the merger and the
appointment of a highly qualified Board of Directors, I look
forward with excitement to building a leading company in the
wound management, plastic surgery and oral care markets. We
are very pleased with our progress in developing products
from our technology platforms. Over the upcoming 12 months
we expect three additional products to be marketed." |
|
|
|
|
|
|
|
Mr. Gray
continued, "The reverse split brings the number of shares
outstanding and the share price more in line with companies
of our size and stage of development. This is the first step
to achieve our ultimate objective of applying for a listing
on NASDAQ or an exchange." |
|
|
|
|
|
|
|
ULURU Inc. is an
emerging specialty pharmaceutical company focused on the
development of a portfolio of wound management, plastic
surgery and oral care products to provide patients and
consumers improved clinical outcomes through controlled
delivery utilizing its innovative transmucosal delivery
system and Hydrogel Nanoparticle Aggregate technology.
|
|
|
|
|
|
|
|
This press
release contains certain statements that are forward-looking
within the meaning of Section 27a of the Securities Act of
1933, as amended, and that involve risks, and uncertainties,
including but not limited to statements made relating to the
establishment of a sales and marketing organization, the
marketing of three additional products and the achievement
of a listing on NASDAQ or an exchange. These statements are
subject to numerous risks, including but not limited to the
risks detailed in the Company's Annual Report on Form 10-K,
for the year ended December 31, 2004, Quarterly Report on
Form 10-Q for the quarter ended September 30, 2005 and other
reports filed by us with the Securities and Exchange
Commission. |
|
|
|
|
|
|
|
Contact Company:
|
|
|
|
|
|
|
|
Kerry P. Gray
President and CEO |
|
|
|
|
|
|
|
Terry K. Wallberg
Chief Financial Officer
(214) 905-5145 |
|
|
|
|
|
|
|
(Back
to 2006 Press Releases) |
|
|
|
|
|